Clinical trial
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00004002 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00004002 |
|---|---|
| Title | PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma |
| Official title | Phase I Trial of PS-341 in Advanced Cancers |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Jul 1, 1999 |
| Primary completion | Oct 1, 2001 |
| First posted | Apr 12, 2004 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: